IL-2 gene-modified tumour vaccines: Monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice

Folia Biologica

Volumn 45, Issue 1, 1999, Pages 7-11

  Indrova M ^a   Pajtasz Piasecka, E ^b   Jandlova T ^a   Simova J ^a   Bubenik J ^a   Radzikowski, C ^b  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERLEUKIN 2; LIVE VACCINE; RECOMBINANT INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLOOD LEVEL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ELIMINATION; GENE INSERTION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL FLUID; PLASMACYTOMA; SARCOMA; STAINING; VACCINATION;

ANIMALIA; MURINAE;

EID: 0032953620     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Abdel-Vahab, Z., Dar, M. M., Hester, D., Vervaert, C., Gangavalli, R., Barber, J., Darrow, T. L., Siegler, H. F. (1996) Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol. 171, 266-254.
2. Berg, K., Hansen, M. B., Nielsen, S. E. (1990) A new sensitive bioassay for precise quantification of interferon activity as measured via mitochondrial dehydrogenase function in cells (MTT method). APMIS 98, 156-162.
3. Bubeník, J. (1993) IL-2 and gene therapy of cancer (Review). Int. J. Oncol. 2, 1049-1052.
4. Bubeník, J. (1996a) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69, 1-14.
5. Bubeník, J. (1996b) Gene transfer for immunotherapy of cancer. Gene Therapy 3, 944-945.
6. Bubeník, J. (1996c) Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Folia Biol. (Praha) 42, 295-304.
7. Bubeník, J., Indrová, M., Němečková, Š., Malkovský, M., von Broen, B., Pálek, V., Anderlíková, J. (1978) Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation tests. Int. J. Cancer 21, 348-355.
8. Bubeník, J., Indrová, M., Perlmann, P., Berzins, K., Mach, O., Kraml, J., Toulcová, A. (1985) Tumour inhibitory effect of TCGF (IL2)-containing preparations. Cancer Immunol. Immunother. 19, 57-61.
9. Bubeník, J., Indrová, M., Šímová, J., Kypěnová, H., Bubeníková, D., Doležalová, K. (1984) Phorbol myristate acetate-stimulated production of interleukin 2 by T-cell lymphoma and constitutive production by derived hybridomas. Neoplasma 31, 497-505.
10. Bubeník, J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubeníková, D., Šímová, J., Jandlová, T. (1988) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19, 279-282.
11. Donohue, J. H., Rosenberg, S. A. (1983) The fate of interleukin-2 after in vivo administration. J. Immunol. 130, 2203-2208.
12. Gillis, S., Ferm, M. M., Ou, W., Smith, K. A. (1978) T-cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120, 2027-2032.
13. Indrová, M., Pajtasz-Piasecka, E., Radzikowski, C., Bubeník, J. (1997) CTLL assay: comparison of two methods for IL-2 determination. Folia Biol. (Praha) 43, 45-47.
14. Karasuyama, H., Melchers, F. (1988) Establishment of mouse cell lines which constituvely secrete large quantities of interleukin 2, 3, 4, or 5 using modified cDNA expression vectors. Eur. J. Immunol. 18, 97-104.
15. Kearney, J. F., Radbruch, A., Liesegang, B., Rajewsky, K. (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123, 1548-1550.
16. Mossman, T. (1988) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
17. Pajtasz-Piasecka, E., Glazman-Kusnierczyk, H., Salwa, J., Konarski, L., Radzikowski, C. (1995) Growth inhibition of transplantable tumours in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent. Arch. Immunol. Ther. Exper. 43, 281-292.
18. Rössner, P., Bubeník, J., Indrová, M., Sobota, V., Vondrys, P., Zeuthen, J., Jandiová, T. Takáč, M. (1997) Genetically modified tumour vaccines: insertion of the IL-2 gene down-regulates tumorigenicity more efficiently than insertion of the CD80 gene. Int. J. Oncol. 10, 77-82.
19. Smith, K. A. (1980a) T-cell growth factor. Immunol. Rev. 51, 377-357.
20. Smith, K. A. (1980b) Continuous cytotoxic T-cell lines. In: Contemporary Topics in Immunobiology, ed. Warner, N.L., pp. 139-155, Plenum Press, New York.
21. Šímová, J., Bubeník, J., Jandlová, T., Indrová, M. (1998) Irradiated IL-2 gene modified plasmacytoma vaccines are more efficient in local therapy due to their higher IL-2 production. Int. J. Oncol. 12, 1195-1198.